Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUW NYSE:JATT NYSE:PLX NASDAQ:TALS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUWBlue Water Acquisition Corp. III$10.34+0.1%$10.31$9.93▼$10.41$290.76MN/A13,640 shs10,755 shsJATTJATT Acquisition$11.31+3.7%$10.91$9.99▼$12.63$90.76MN/A20,484 shs17,630 shsPLXProtalix BioTherapeutics$2.37$2.19$1.41▼$3.19$190.96MN/A960,003 shs212,184 shsTALSTalaris Therapeutics$47.98$18.84$0.89▼$27.95$2.05B2.18386,531 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUWBlue Water Acquisition Corp. III0.00%+0.15%+0.29%+0.78%+7.37%JATTJATT Acquisition0.00%+1.03%+8.75%+5.94%+573.21%PLXProtalix BioTherapeutics0.00%-0.42%+6.76%+8.72%+48.13%TALSTalaris Therapeutics0.00%0.00%0.00%0.00%+154.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUWBlue Water Acquisition Corp. III$10.34+0.1%$10.31$9.93▼$10.41$290.76MN/A13,640 shs10,755 shsJATTJATT Acquisition$11.31+3.7%$10.91$9.99▼$12.63$90.76MN/A20,484 shs17,630 shsPLXProtalix BioTherapeutics$2.37$2.19$1.41▼$3.19$190.96MN/A960,003 shs212,184 shsTALSTalaris Therapeutics$47.98$18.84$0.89▼$27.95$2.05B2.18386,531 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUWBlue Water Acquisition Corp. III0.00%+0.15%+0.29%+0.78%+7.37%JATTJATT Acquisition0.00%+1.03%+8.75%+5.94%+573.21%PLXProtalix BioTherapeutics0.00%-0.42%+6.76%+8.72%+48.13%TALSTalaris Therapeutics0.00%0.00%0.00%0.00%+154.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUWBlue Water Acquisition Corp. III 1.00SellN/AN/AJATTJATT Acquisition 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$12.00406.33% UpsideTALSTalaris Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TALS, BLUW, PLX, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026BLUWBlue Water Acquisition Corp. III Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/A$0.42 per share27.08($0.53) per shareN/APLXProtalix BioTherapeutics$76.38M2.50$0.13 per share17.80$0.47 per share5.04TALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/APLXProtalix BioTherapeutics$8.31M$0.18N/A7.65N/A-21.03%-30.89%-11.74%N/ATALSTalaris Therapeutics-$73.89M-$1.79N/AN/AN/AN/A-39.93%-37.37%N/ALatest TALS, BLUW, PLX, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLUWBlue Water Acquisition Corp. IIIN/A$0.08N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AJATTJATT AcquisitionN/A0.150.15PLXProtalix BioTherapeuticsN/A1.981.27TALSTalaris TherapeuticsN/A15.4115.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUWBlue Water Acquisition Corp. IIIN/AJATTJATT Acquisition47.97%PLXProtalix BioTherapeutics16.53%TALSTalaris Therapeutics67.61%Insider OwnershipCompanyInsider OwnershipBLUWBlue Water Acquisition Corp. IIIN/AJATTJATT Acquisition20.00%PLXProtalix BioTherapeutics6.70%TALSTalaris Therapeutics16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUWBlue Water Acquisition Corp. III228.12 millionN/ANot OptionableJATTJATT Acquisition38.03 million13.80 millionNot OptionablePLXProtalix BioTherapeutics20080.57 million69.00 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableTALS, BLUW, PLX, and JATT HeadlinesRecent News About These CompaniesTalaris TherapeuticsJuly 6, 2026 | fool.comTourmaline Bio, Inc. (TRML)August 21, 2024 | finance.yahoo.comCoin Tales Free Spins – Updated Every Day!July 30, 2024 | talkandroid.comTCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 29, 2024 | finanznachrichten.deLongitude Venture Partners III, L.P.'s Net WorthFebruary 25, 2024 | benzinga.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15November 1, 2023 | msn.comTalaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complexOctober 20, 2023 | dhakatribune.comDTalaris Therapeutics goes ex-dividend tomorrowOctober 19, 2023 | msn.comTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 18, 2023 | finanznachrichten.deTalaris shareholders approve merger, 1-for-10 reverse stock splitOctober 17, 2023 | msn.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | finance.yahoo.comTalaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling AlertOctober 16, 2023 | knoxdaily.comKShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerOctober 6, 2023 | marketwatch.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioOctober 6, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsOctober 4, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateSeptember 12, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,August 23, 2023 | bakersfield.comBSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 15, 2023 | markets.businessinsider.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 14, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFAugust 8, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20262 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 20263 Rare-Earth ETFs That Help Investors Balance Exposure and RiskBy Chris Markoch | July 12, 2026The AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026By Chris Markoch | July 3, 2026TALS, BLUW, PLX, and JATT Company DescriptionsBlue Water Acquisition Corp. III NASDAQ:BLUW$10.34 +0.02 (+0.15%) As of 07/24/2026 03:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Blue Water Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.JATT Acquisition NYSE:JATT$11.31 +0.40 (+3.67%) Closing price 07/24/2026 03:54 PM EasternExtended Trading$11.24 -0.08 (-0.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Protalix BioTherapeutics NYSE:PLX$2.37 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.37 +0.00 (+0.13%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Talaris Therapeutics NASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
